GPT2 and myeloid sarcoma: GPT2 expression levels varied significantly among the GBM subtypes (p < 0.0001, Kruskal–Wallis test) with lower levels in MS than G-CIMP (p < 0.0005), PN (p < 0.05), and CS (p < 0.05, Dunn test).